Liver TransplantPhase 2IMMUNO-THNCT06254248
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
A Phase 2 study testing Systemic therapy in people with Liver Transplant and Hepatocellular Carcinoma Recurrent, run by Assistance Publique - Hôpitaux de Paris at 10 sites in France.
Trial summary
The prognosis of liver transplanted (LT) patients with recurrence of hepatocellular carcinoma (HCC), especially those with progression after locoregional treatment or advanced HCC, remains poor. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment
- What is being tested?
- Systemic therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 10 sitesFrance
- Study dates
- 22 Jan 2026to 1 Jan 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients over 18 and under 90 years old:
- who underwent LT more than 6 months ago (to prevent the higher risk of ACR which exists within the first months after LT and to deal with populations with a lowered immunosuppressive regimen long after LT)
- with HCC recurrence diagnosis according to the EASL diagnostic criteria (33)
- with advanced HCC not accessible to surgery and locoregional treatment
- with at least one measurable untreated lesion
- With a proposal for Atezo-Beva in first line treatment made in a multidisciplinary meeting
Show all 21Show fewer
- Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment, unless otherwise specified:
- ANC ≥ 1.5 x 109/L (1500/µL) without granulocyte colony-stimulating factor support
- Lymphocyte count ≥ 0.5 x 109/L (500/µL)
- Platelet count ≥ 75 x 109/L (75,000/µL) without transfusion
- Hemoglobin ≥ 90 g/L (9 g/dL). Patients may be transfused to meet this criterion.
- AST, ALT ≤ 5 x upper limit of normal (ULN)
- Serum bilirubin ≤ 3x ULN
- creatinine clearance≥40 mL/min (calculated using the Cockcroft-Gault formula)
- For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 2x ULN
- Urine dipstick for proteinuria < 2+ (within 7 days prior to initiation of study treatment). Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate <1 g of protein in 24 hours
- ECOG Performance Status of 0 or 1
- For women of childbearing potential and men: agreement to remain abstinent or use effective contraception during treatment and at least :
- 5 months after the end of the treatment with atezolizumab,
- 6 months after the end of the treatment with bevacizumab
- Child-Pugh class A
Who cannot join
- History of ACR within 3 months before starting Atezo-Beva treatment
- Banff score for ACR ≥ 3 on liver biopsy performed before the initiation of the treatment
- Pregnant or breastfeeding woman
- Patient not affiliated to a beneficiary or entitled social security scheme or to the PUMA
- Patient not having signed consent
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT-scan
Show all 22Show fewer
- History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment.
- Inadequately controlled arterial hypertension (defined as systolic blood pressure (BP) ≥ 160 mmHg and/or diastolic blood pressure > 100 mmHg), based on an average of ≥ 3 BP readings on ≥ 2 sessions Anti-hypertensive therapy to achieve these parameters is allowable.
- Prior history of hypertensive crisis or hypertensive encephalopathy
- History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration
- Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
- Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses
- Hypersensitivity to the active substance or to any of the excipients of the SmPC of bevacizumab and the SmPC of atezolizumab
- Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
- Prior arterial thromboembolic reactions including cerebrovascular accidents, transient ischaemic attacks and myocardial infarctions;
- Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
- In case of proteinuria > 1g in 24 hours
- History of leptomeningeal disease
- Active tuberculosis
- Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
Trial locations and contacts
10 sites in 1 country. Contact the study team or a site near you to ask about taking part.
10 sites in 1 country
France10 sites, 10 recruiting
- Recruiting
Hôpital Beaujon
Clichy, 92110
Mohamed BOUATTOUR, MD, 140875614 ext. +33, mohamed.bouattour@aphp.fr
- Recruiting
Hôpital Henri-Mondor
Créteil, 94010
Giuliana AMADDEO, MD, 149812367 ext. +33, giuliana.amaddeo@aphp.fr
- Recruiting
Hôpital Claude Huriez - CHU de Lille
Lille, 59037
Massih NINGARHARI, MD, 320444337 ext. +33, massih.ningarhari@chu-lille.fr
- Recruiting
Lyon - Hôpital Croix Rousse
Lyon, 69004
Teresa ANTONINI, MD, 426732654 ext. +33, teresa.antonini@chu-lyon.fr
- Recruiting
CHU Montpellier - Hôpital Saint Eloi
Montpellier, 34295
Stéphanie FAURE, MD, 467337064 ext. +33, s-faure@chu-montpellier.fr
- Recruiting
Hôpital Pitié-Salpêtrière
Paris, 75013
Manon ALLAIRE, MD, 142127064 ext. +33, manon.allaire@aphp.fr
- Recruiting
CHU Rennes - Hôpital Pontchaillou
Rennes, 35033
Thomas UGUEN, MD, 299282525 ext. +33, thomas.uguen@chu-rennes.fr
- Recruiting
Hôpital de Hautepierre - Strasbourg
Strasbourg, 67200
Camille BESCH, MD, 388127268 ext. +33, camille.besch@chru-strasbourg.fr
- Recruiting
CHU Tours - Hôpital Trousseau
Tours, 37044
Ephrem SALAME, MD, PhD, 247475937 ext. +33, e.salame@chu-tours.fr
- Recruiting
Hôpital Paul Brousse
Villejuif, 94800
Olivier ROSMORDUC, MD, PhD, 145596540 ext. +33, olivier.rosmorduc@aphp.fr
About this study
The prognosis of liver transplanted (LT) patients with recurrence of hepatocellular carcinoma (HCC), especially those with progression after locoregional treatment or advanced HCC, remains poor. Current treatment modalities involve tyrosine kinase inhibitors (TKIs) characterized by a low response rate and often poor tolerability. Encouraging findings from the Imbrave 150 study, demonstrating increased survival rates coupled with favorable treatment tolerance, prompt the investigators to consider the potential of offering the combination of treatment with Atezolizumab-Bevacizumab (Atezo-Beva) to patients with LT. No data regarding the safety and efficacy of this new combination are available for patients with LT as they were not included in Imbrave 150. Immunosuppression after LT is low when compared to essentially all other organ recipients, liver recipients are considered with lower immunological risk. However, the use of ICIs has been associated with a risk of hepatic rejection in LT patients. In this study, in order to prevent acute cellular rejection (ACR) occurrence, we propose to adopt a standardized immunosuppressive regimen closed to the one used immediately after LT but with lower therapeutic goals for tacrolimus and everolimus to allow immunotherapy treatment to be effective. The better tolerance of liver grafts will probably lead to less risk of rejection with Atezo-Beva than in other organ transplants.
Read the detailed description
Open-label multicentric single-arm two-stage phase 2 trial. Population: Adult LT patients with advanced HCC recurrence with indication to systemic treatment Primary objective: To study the safety (ACR on histology) at 6 months of the first-line Atezo-Beva combination in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection.
Primary endpoint: Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center).
Secondary objective:
To study the safety (ACR on histology) at 24 months and at the end of Atezo-Beva treatment in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection.
- To assess the efficacy and tolerance of first-line Atezo-Beva combination in LT patients with advanced HCC in association with a standardized immunosuppressive treatment to prevent the risk of ACR based on:
- the Progression Free Survival (PFS)
- the Overall survival (OS)
- the objective response rate (ORR) (complete and partial response)
- the duration of response
- the quality of life of the patients under Atezo-Beva treatment
- To compare the efficacy (OS and PFS) of LT patients treated by Atezo- Beva treatment to an historical retrospective cohort of LT patients already available treated by TKI as first line (external arm comparison)
- To assess the adverse events related to Atezo-Beva treatment in LT patients with recurrent advanced HCC.
- To assess the evolution of the level of donor specific antibodies (DSA) during Atezo-Beva treatment and its association with ACR, PFS and OS.
Translational research/ancillary studies:
- To assess the association before the first injection between the risk of ACR, PFS, OS and side effects and
- the "Immunome" imaging on tumor sample and non-tumoral liver sample to quantify and regionalize immune populations on pathology (Multispectral Imaging, Mantra)
- the Leukocyte DNA analysis to identify constitutional genetic variants
- To assess the association before the first injection or just before the second injection and at 3 months between the risk of ACR, PFS, OS and side effects and
- the "immunomonitoring" on blood sample (frequency and/or the phenotype of circulating immune cells)
- the presence of tumors cells (liquid biopsies)
- the presence of circulating tumor DNA and the type of mutations
- the presence of circulating proteins
- the profile of circulating exosomes
- Being tested
- Systemic therapy
- Keywords
- HCC, systemic therapy, graft rejection, immunotherapy, Atezolizumab-Bevacizumab
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Systemic therapyDrug
Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:
Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept.
| Study group | Role | What they receive |
|---|---|---|
| Atezo-Beva combination | Experimental | first-line Atezo-Beva combination in LT patients with advanced HCC in association with a standardized immunosuppressive treatment to prevent the risk of acute cellular rejection Receives: Drug: Systemic therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center)
To study the safety (ACR on histology) at 6 months of the first-line Atezo-Beva combination in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection
Measured: 6 months
Secondary outcomes (9)
Rate of Acute Cellular Rejection (ACR) at 24 months
Rate of ACR (defined by a Histological Banff score ≥ 5) at 24 months (confirmed by a second external expert center.
Measured: 24 months
Rate of Acute Cellular Rejection (ACR) at the end of Atezo-Beva treatment
Rate of ACR (defined by a Histological Banff score ≥ 5) at 24 months and at the end of Atezo-Beva treatment (confirmed by a second external expert center.
Measured: at the end of treatment
Progression Free Survival (PFS)
The Progression Free Survival (PFS) is defined as the time from inclusion to disease progression according to RECIST 1.1 on imaging (CT-scan) performed every 3 months or death from any cause, whichever occurred first.
Measured: between the inclusion and 24 months after the last inclusion
Overall survival (OS)
The Overall survival (OS) defined by the time from inclusion to death from any cause
Measured: between the inclusion and 24 months after the last inclusion
Objective Response Rate (ORR)
The Objective Response Rate (ORR) at 12 months is defined as the percentage of patients with a confirmed complete or partial response according to RECIST 1.1 criteria on imaging (CT-scan) performed every 3 months.
Measured: 12 months
Duration of response
The Duration of response is defined by the time from first documentation of complete or partial response to disease progression or death according to RECIST 1.1 criteria on imaging (CT-scan) performed every 3 months.
Measured: between the inclusion and 24 months after the last inclusion
Time to deterioration of quality of life
The time to deterioration of quality of life is defined as the time from inclusion to the first deterioration of quality of life as reported by the patient, with deterioration defined as a decrease from baseline of 10 points or more on the EORTC QLQ-C30 maintained for two consecutive assessments or a decrease of 10 points or more in one assessment followed by death from any cause within 3 weeks. Each quality of life evaluation will be reported by the patient using EORTC QLQ-C30 score fill formed every 6 months until 24 months after the initiation of the treatment.
Measured: between the inclusion and 24 months after the last inclusion
Type, frequency and severity of adverse events and serious adverse events
They will be assessed on the basis of the nature, frequency and severity of adverse events according to NCI Common Terminology Criteria for Adverse Events, version 4.0. The management of side effects usually observed under immunotherapy will be managed according to the American Society of Clinical Oncology Clinical Practice Guidelines
Measured: between the inclusion, at the end of Atezo-Bev treatment and up to 24 months
Donor Specific Antibodies (DSA) median
DSA will be assessed and correlation to ACR, the PFS and OS will be evaluated
Measured: baseline and at Day 21, 3 Months 6 Months , 12 Months , 18 Months , 24 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2024
- Study start22 Jan 2026
- Primary completion1 Jan 2030 (estimated)
- Study completion1 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver TransplantStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06254248
- Sponsor's protocol ID
- APHP230899
- Other IDs
- 2024-514400-14-00
- Acronym
- IMMUNO-TH
- Status last verified
- Mar 2026
- First submitted
- 12 Jan 2024
- Last updated
- 10 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
- ClinicalTrials.gov ID
- NCT06254248
- Acronym / sponsor ID
- IMMUNO-TH / APHP230899
- Keywords
- HCC, systemic therapy, graft rejection, immunotherapy, Atezolizumab-Bevacizumab
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 22 Jan 2026 (actual)
- Primary completion
- 1 Jan 2030 (estimated)
- Study completion
- 1 Jan 2030 (estimated)
- First posted
- 12 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prognosis of liver transplanted (LT) patients with recurrence of hepatocellular carcinoma (HCC), especially those with progression after locoregional treatment or advanced HCC, remains poor. Current treatment modalities involve tyrosine kinase inhibitors (TKIs) characterized by a low response rate and often poor tolerability. Encouraging findings from the Imbrave 150 study, demonstrating increased survival rates coupled with favorable treatment tolerance, prompt the investigators to consider the potential of offering the combination of treatment with Atezolizumab-Bevacizumab (Atezo-Beva) to patients with LT. No data regarding the safety and efficacy of this new combination are available for patients with LT as they were not included in Imbrave 150. Immunosuppression after LT is low when compared to essentially all other organ recipients, liver recipients are considered with lower immunological risk. However, the use of ICIs has been associated with a risk of hepatic rejection in LT patients. In this study, in order to prevent acute cellular rejection (ACR) occurrence, we propose to adopt a standardized immunosuppressive regimen closed to the one used immediately after LT but with lower therapeutic goals for tacrolimus and everolimus to allow immunotherapy treatment to be effective. The better tolerance of liver grafts will probably lead to less risk of rejection with Atezo-Beva than in other organ transplants.
Detailed description
Open-label multicentric single-arm two-stage phase 2 trial. Population: Adult LT patients with advanced HCC recurrence with indication to systemic treatment Primary objective: To study the safety (ACR on histology) at 6 months of the first-line Atezo-Beva combination in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection.
Primary endpoint: Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center).
Secondary objective:
To study the safety (ACR on histology) at 24 months and at the end of Atezo-Beva treatment in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection.
- To assess the efficacy and tolerance of first-line Atezo-Beva combination in LT patients with advanced HCC in association with a standardized immunosuppressive treatment to prevent the risk of ACR based on:
- the Progression Free Survival (PFS)
- the Overall survival (OS)
- the objective response rate (ORR) (complete and partial response)
- the duration of response
- the quality of life of the patients under Atezo-Beva treatment
- To compare the efficacy (OS and PFS) of LT patients treated by Atezo- Beva treatment to an historical retrospective cohort of LT patients already available treated by TKI as first line (external arm comparison)
- To assess the adverse events related to Atezo-Beva treatment in LT patients with recurrent advanced HCC.
- To assess the evolution of the level of donor specific antibodies (DSA) during Atezo-Beva treatment and its association with ACR, PFS and OS.
Translational research/ancillary studies:
- To assess the association before the first injection between the risk of ACR, PFS, OS and side effects and
- the "Immunome" imaging on tumor sample and non-tumoral liver sample to quantify and regionalize immune populations on pathology (Multispectral Imaging, Mantra)
- the Leukocyte DNA analysis to identify constitutional genetic variants
- To assess the association before the first injection or just before the second injection and at 3 months between the risk of ACR, PFS, OS and side effects and
- the "immunomonitoring" on blood sample (frequency and/or the phenotype of circulating immune cells)
- the presence of tumors cells (liquid biopsies)
- the presence of circulating tumor DNA and the type of mutations
- the presence of circulating proteins
- the profile of circulating exosomes
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Atezo-Beva combination | Experimental | Drug: Systemic therapyfirst-line Atezo-Beva combination in LT patients with advanced HCC in association with a standardized immunosuppressive treatment to prevent the risk of acute cellular rejection |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (21 listed)
- All patients over 18 and under 90 years old:
- who underwent LT more than 6 months ago (to prevent the higher risk of ACR which exists within the first months after LT and to deal with populations with a lowered immunosuppressive regimen long after LT)
- with HCC recurrence diagnosis according to the EASL diagnostic criteria (33)
- with advanced HCC not accessible to surgery and locoregional treatment
- with at least one measurable untreated lesion
Key exclusion criteria (22 listed)
- History of ACR within 3 months before starting Atezo-Beva treatment
- Banff score for ACR ≥ 3 on liver biopsy performed before the initiation of the treatment
- Pregnant or breastfeeding woman
- Patient not affiliated to a beneficiary or entitled social security scheme or to the PUMA
- Patient not having signed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Systemic therapyAtezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment: Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept. | Drug | Atezo-Beva combination |
Primary outcome
Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center)
Time frame: 6 months
To study the safety (ACR on histology) at 6 months of the first-line Atezo-Beva combination in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection
9 secondary outcomes
Rate of Acute Cellular Rejection (ACR) at 24 months
Time frame: 24 months
Rate of Acute Cellular Rejection (ACR) at the end of Atezo-Beva treatment
Time frame: at the end of treatment
Progression Free Survival (PFS)
Time frame: between the inclusion and 24 months after the last inclusion
Overall survival (OS)
Time frame: between the inclusion and 24 months after the last inclusion
Objective Response Rate (ORR)
Time frame: 12 months
Duration of response
Time frame: between the inclusion and 24 months after the last inclusion
Time to deterioration of quality of life
Time frame: between the inclusion and 24 months after the last inclusion
Type, frequency and severity of adverse events and serious adverse events
Time frame: between the inclusion, at the end of Atezo-Bev treatment and up to 24 months
Donor Specific Antibodies (DSA) median
Time frame: baseline and at Day 21, 3 Months 6 Months , 12 Months , 18 Months , 24 Months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2026.
Related trials for Liver Transplant
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
RecruitingPhase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Liver Transplant
RecruitingObservational study
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Systemic therapy in people with Liver Transplant and Hepatocellular Carcinoma Recurrent, run by Assistance Publique - Hôpitaux de Paris at 10 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Manon Allaire, MD (142127064 ext. +33, manon.allaire@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2026.